The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three-year highs in response to breakthrough innovations and ...

Exelixis (EXEL) stock in focus as U.S. FDA leaves out an AdCom in its review of the firm's label expansion for cancer therapy ...

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

There's another legal issue for Mr. Denise Richards. The post Denise Richards’ Husband Aaron Phypers Sued for Alleged Fraud ...

US FDA accepts and grants priority review status to Dizal’s sunvozertinib NDA in relapsed or refractory NSCLC patients with EGFR exon20ins: Shanghai Thursday, January 9, 2025, 1 ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Stephen Baldwin’s stint on Special Forces was short but memorable — and we’re not just talking about his skinny black headband. Hailey Bieber’s 58-year-old dad was the first star to leave during the ...

Aaron Phypers, Denise Richards' husband, faces fraud lawsuit over stem cell treatments at his Malibu wellness center.

Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Sectors of Business IRVINE, Calif. & ...

In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting ?-catenin, a historically "undruggable" protein, in just two months. This ...

In a recent achievement, DP Technology's hit discovery platform RiDYMO® has successfully designed a cyclic peptide ...